SCHEMBL5916991

SCHEMBL5916991

Cc1ccnc(-n2[se]c3ccccc3c2=O)n1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ METAP2 P50579 6/20 0.54
▸ MPI P34949 3/20 0.53
▸ KDM4E B2RXH2 2/20 0.53
▸ MEN1 O00255 2/20 0.53
▸ PMM2 O15305 2/20 0.53
▸ ALDH1A1 P00352 2/20 0.53
▸ POLB P06746 2/20 0.53
▸ MAPT P10636 2/20 0.53
▸ G6PD P11413 2/20 0.53
▸ PKM P14618 2/20 0.53
▸ HPGD P15428 2/20 0.53
▸ ALOX15 P16050 2/20 0.53
▸ ALOX12 P18054 2/20 0.53
▸ KMT2A Q03164 2/20 0.53
▸ HSD17B10 Q99714 2/20 0.53
▸ TDP1 Q9NUW8 2/20 0.53
▸ MAPK1 P28482 1/20 0.53
▸ EP300 Q09472 1/20 0.53
▸ KAT2A Q92830 1/20 0.53
▸ KAT2B Q92831 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5916782 0.84 METAP2 (0.61) METAP2MPIKDM4EMEN1PMM2
SCHEMBL5916551 0.83 METAP2 (0.58) METAP2MPIKDM4EMEN1PMM2
SCHEMBL10744770 0.82 KDM4E (0.44) METAP2MPIKDM4EMEN1PMM2
SCHEMBL5917047 0.79 METAP2 (0.56) METAP2MPIKDM4EMEN1PMM2
SCHEMBL30573260 0.78 METAP2 (0.60) METAP2MPIKDM4EMEN1PMM2
SCHEMBL5916688 0.78 MPI (0.58) METAP2MPIKDM4EMEN1PMM2
SCHEMBL5916764 0.78 METAP2 (0.52) METAP2MPIKDM4EMEN1PMM2
SCHEMBL5916772 0.77 METAP2 (0.54) METAP2MPIKDM4EMEN1PMM2
SCHEMBL30530469 0.75 METAP2 (0.57) METAP2MPIKDM4EMEN1PMM2
SCHEMBL1353489 0.75 METAP2 (0.57) METAP2MPIKDM4EMEN1PMM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1541145-A1 THE USE OF BENZISOSELENAZOLONE COMPOUNDS AGAINST ISCHEMIC MYOCARDIAL DAMAGE Institute of Materia, Chinese Academy of Medical Sciences (CN) 2005-06-15 — — EP claimed
US-20060135569-A1 Use of benzisoselenazolone compounds against ischemic myocardial damage INSTITUTE OF MATERIA MEDICA CHINESE ACADEMY OF MEDICAL SCIENCES (CN) 2006-06-22 — — US disclosed
EP-1541145-A1 THE USE OF BENZISOSELENAZOLONE COMPOUNDS AGAINST ISCHEMIC MYOCARDIAL DAMAGE Institute of Materia, Chinese Academy of Medical Sciences (CN) 2005-06-15 — — EP disclosed
US-4711961-A Benzisoselenazolethiones and process for the treatment of various diseases in humans A. NATTERMANN & CIE GMBH (DE) 1987-12-08 — — US disclosed
US-4550168-A Benzisoselenazolones and a process for the treatment of inflammatory diseases A. NATTERMANN & CIE GMBH (DE) 1985-10-29 — — US disclosed
EP-0100899-A2 Benzisoselenazolones, process for their preparation and pharmaceutical compositions containing them A. Nattermann & Cie. GmbH (DE) 1984-02-22 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060135569-A1 Use of benzisoselenazolone compounds against ischemic myocardial damage TNNI3, TNNT2, MYLK2 METAP2 4321/4885MPI 819/4885KDM4E 2585/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback